Adjuvant treatments for triple-negative breast cancers

Annals of Oncology

Volumn 23, Issue SUPPL. 6, 2012, Pages

  Joensuu, H ^a   Gligorov, J ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b HÔPITAL TENON   (France)

Author keywords

Adjuvant; Anthracycline; Capecitabine; Chemotherapy; Taxane; Triple negative breast cancer

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; IXABEPILONE; METHOTREXATE; OLAPARIB; PACLITAXEL; PANITUMUMAB; RUCAPARIB; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VELAPARIB;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CORONARY ARTERY SPASM; DIARRHEA; DISEASE FREE SURVIVAL; DNA REPAIR; DRUG EFFICACY; DRUG MEGADOSE; HEART ARRHYTHMIA; HUMAN; MAINTENANCE CHEMOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; THORAX PAIN; TRIPLE NEGATIVE BREAST CANCER; UNSPECIFIED SIDE EFFECT;

EID: 84867129194     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds194     Document Type: Article

References (37)

1. Yamamoto Y, Iwase H. Clinicopathological features and treatment strategy for triple-negative breast cancer. Int J Clin Oncol 2010; 15: 341-351.
2. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011; 5: 5-23.
3. Prat A, Parker JS, Karginova O et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12: R68.
4. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Breast Cancer v2. 2011. Available at: http://www.nccn.org/professionals/physician_gls/breast.pdf (21 August 2012, date last accessed).
5. Goldhirsch A, Wood WC, Coates AS et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St.: Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747.
6. St-Paul de Vence. Recommandations pour la pratique clinique: Nice-Saint-Paulde-Vence 2009 cancers du sein « et soins de support » Prise en charge du cancer du sein infiltrant de la femme non ménopausée-Cancers du sein. Oncologie 2009; 11: 507-532.
7. Aebi S, Davidson T, Gruber G et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl. 5): vi12-vi24.
8. Schwentner L, Wolters R, Wischnewsky M et al. Triple-negative breast cancer: the effect of guideline-adherent adjuvant treatment on the cumulative survival-a retrospective multicenter cohort study of 3,658 patients. J Clin Oncol 2011; 29 (Suppl): Abstr 1063.
9. Perez EA, Moreno-Aspitia A, Aubrey Thompson E et al. Adjuvant therapy of triple negative breast cancer. Breast Cancer Res Treat 2010; 120: 285-291.
10. Colleoni M, Cole BF, Viale G et al. Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Clin Oncol 2010; 28: 2966-2973.
11. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and longterm survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-1281.
12. Cheang M, Chia SK, Tu D et al. Anthracyclines in basal breast cancer: The NCIC-CTG trial MA5 comparing adjuvant CMF to CEF. J Clin Oncol 2009; 27: 519.
13. Rocca A, Paradiso A, Sismondi P et al. Benefit from CMF with or without anthracyclines in relation to biologic profiles in early breast cancer. J Clin Oncol 2011; 29s: Abstr 1031.
14. Laporte S, Jones S, Chapelle C et al. Consistency of effect of docetaxelcontaining adjuvant chemotherapy in patients with early stage breast cancer independent of nodal status: meta-analysis of 12 randomized clinical trials. Cancer Res 2009; 69 (Suppl 1): Abstr 605.
15. Martin M, Segui MA, Anton A et al. Adjuvant docetaxel for high-risk, nodenegative breast cancer. N Engl J Med 2010; 363: 2200-2210.
16. Hugh J, Hanson J, Cheang MC et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009; 27: 1168-1176.
17. Hayes DF, Thor AD, Dressler LG et al. HER2 and response to paclitaxel in nodepositive breast cancer. N Engl J Med 2007; 357: 1496-1506.
18. Sparano JA, Wang M, Martino S et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358: 1663-1671.
19. Muss HB, Berry DA, Cirrincione CT et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009; 360: 2055-2065.
20. Joensuu H, Kellokumpu-Lehtinen P-L, Huovinen R et al. FinXX final 5-year analysis: results of the randomised, open-label, phase III trial in medium-to-high risk early breast cancer. Cancer Res 2010; 70 (Suppl. 2): Abstr S4-1.
21. Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncol 2009; 10: 1145-1151.
22. O'Shaughnessy J, Paul D, Stokoe C et al. First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer. Cancer Res 2010; 70 (Suppl. 2): Abstr S4-2.
23. Lluch A, Torrecillas L, Barrios CH et al. CIBOMA/2004-01: a randomised phase III trial assessing adjuvant capecitabine (X) maintenance therapy after standard chemotherapy for triple-negative early breast cancer (EBC). Eur J Cancer Suppl 2009; 7: 304.
24. Silver DP, Richardson AL, Eklund AC et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 2010; 28: 1145-1153.
25. Leong CO, Vidnovic N, DeYoung MP et al. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 2007; 117: 1370-1380.
26. Gray R, Bhattacharya S, Bowden C et al. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009; 27: 4966-4972.
27. Miles DW, Chan A, Dirix LY et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28: 3239-3247.
28. Robert NJ, Dieras V, Glaspy J et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29: 1252-1260.
29. Brufsky A, Valero V, Tiangco B et al. Impact of bevacizumab (BEV) on efficacy of second-line chemotherapy (CT) for triple-negative breast cancer (TNBC): analysis of RIBBON-2. J Clin Oncol 2011; 29s: Abstr 1010.
30. Baselga J, Stemmer S, Pego A et al. Cetuximab + cisplatin in estrogen receptornegative, progesterone receptor-negative, HER2-negative (triple-negative) metastatic breast cancer: results of the randomized phase II BALI-1 trial. Cancer Res 2010; 70: S2: Abstr PD01-01.
31. Nabholtz J, Weber B, Mouret-Reynier M et al. Panitumumab in combination with FEC 100 (5-fluorouracil, epidoxorubicin, cyclophosphamide) followed by docetaxel (T) in patients with operable, triple-negative breast cancer (TNBC): preliminary results of a multicenter neoadjuvant pilot phase II study. J Clin Oncol 2011; 29 (suppl): Abstr e11574.
32. Tutt A, Robson M, Garber JE et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376: 235-244.
33. Gluz O, Nitz UA, Harbeck N et al. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Ann Oncol 2008; 19: 861-870.
34. Rodenhuis S, Bontenbal M, van Hoesel QG et al. Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. Ann Oncol 2006; 17: 588-596.
35. Nieto Y, Shpall EJ. High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted? Curr Opin Oncol 2009; 21: 150-157.
36. Berry DA, Ueno NT, Johnson MM et al. High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol 2011; 29: 3214-3223.
37. Bonilla L, Ben-Aharon I, Vidal L et al. Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst 2010; 102: 1845-1854.